13/06/2019 - Bone Therapeutics´ allogeneic cell therapy product ALLOB meets primary endpoints in Phase IIa study in patients undergoing a lumbar spinal fusion
(WorldNews Belgium)

Regulated Information - Inside Information Bone Therapeutics` allogeneic cell therapy product, ALLOB, meets primary endpoints in Phase IIa study in patients undergoing a lumbar spinal fusion procedure Conference call and presentation Bone Therapeutics` management and Professor Bronek Boszczyk will host a conference call today at 3 pm CEST. The presentation that will be used during the call can be accessed by clicking here. To participate in the Q&A, please dial one of the numbers below ten minutes in advance, using confirmation code 7885631. The conference call will be conducted in English. Belgium: +32 (0)2 400 98 74 France: +33 (0)1 76 700 794 United Kingdom: +44 (0)8445718892 United...